TaTME

PROCEDURE4 trials

Sponsors

Amsterdam UMC, location VUmc, Sun Yat-sen University, Case Comprehensive Cancer Center, Cantonal Hospital of St. Gallen

Conditions

MortalityPostoperative MorbidityRectal CancerRectal CarcinomaRectal Neoplasms MalignantRecurrenceSurgerySurvival

Phase 3

COLOR III Trial: Transanal vs Laparoscopic TME

Amsterdam UMC, location VUmcRectal Carcinoma, Surgery

Start: 2016-12-02End: 2025-05-31Target: 1104Updated: 2019-06-06

Unknown Phase

Transanal Versus Laparoscopic Total Mesorectal Excision for Rectal Cancer

RecruitingNCT02966483

Sun Yat-sen UniversityRectal Neoplasms Malignant, Surgery

Start: 2016-04-30End: 2026-07-31Target: 1114Updated: 2025-01-17

Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence

Active, not recruitingNCT03283540

Case Comprehensive Cancer CenterRectal Cancer

Start: 2017-09-25End: 2025-08-31Updated: 2025-08-17

Abdominal or Transanal TME for Rectal Cancer Therapy

Cantonal Hospital of St. GallenMortality, Postoperative Morbidity, Recurrence +1

Start: 2012-01-01End: 2023-12-31Target: 300Updated: 2023-08-08

Related Papers

Transanal vs Laparoscopic Total Mesorectal Excision and 3-Year Disease-Free Survival in Rectal Cancer

JAMA2025-01-2315 citations

Three-year disease-free survival after transanal vs. laparoscopic total mesorectal excision for rectal cancer (TaLaR): A randomized clinical trial.

Journal of Clinical Oncology2024-06-011 citations

Report from ‘ESCP 2021 Virtual’: the 16th Scientific and Annual Conference of the European Society of Coloproctology, 22–24 September 2021

Colorectal Disease2022-01-202 citations

Comparison of pathological outcomes after transanal versus laparoscopic total mesorectal excision: a prospective study using data from randomized control trial.

2019-10-0424 citations